Complement Therapeutics
↗United Kingdom (University of Manchester spinout, with facilities in UK and Germany)
Complement Therapeutics is an early-stage biotechnology company focused on discovering and developing novel therapeutics for complement-mediated diseases. Spun out from The University of Manchester in March 2020, the company leverages groundbreaking research on the complement system and its role in human disease. The company's lead program, CTx001, is an AAV-based gene therapy designed to deliver a truncated Complement Receptor 1 (mini-CR1) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), a disease affecting 5 million people globally with 1.5 million cases in the US alone. Beyond its clinical pipeline, Complement Therapeutics has developed the Complement Precision Medicine platform, a proprietary mass spectrometry diagnostic tool enabling simultaneous measurement of complement proteins from blood samples for precision medicine approaches.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Gene Therapy, Ophthalmology, Complement-Mediated Diseases
SIZE & FINANCIALS
Employees:51-200
Founded:2020
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:€77M
Investors:Gimv (Series A lead), Forbion (co-lead Series A, seed investor), BioGeneration Ventures (BGV) (seed and Series A), Panakès Partners, Cambridge Innovation Capital (CIC), Hadean Ventures, Seroba Life Sciences
PIPELINE
Stage:Phase I/II
Lead Drug Stage:Phase I/II
Modalities:Gene Therapy (AAV), Protein Therapeutics (Complement regulators)
Active Trials:1
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Pharmaron (Liverpool, UK CDMO for clinical manufacturing and GMP production), Cell and Gene Therapy Catapult (manufacturing process optimization), University of Manchester (scientific collaboration)
COMPETITION
Position:Leader
Competitors:Novartis (Gyroscope Therapeutics asset, but recently discontinued), Astellas/Audentes (other AAV gene therapy programs), Spark Therapeutics (ophthalmology gene therapy), Other complement-targeted therapeutics companies
LEADERSHIP
Key Executives:
Dr. Rafiq Hasan - Chief Executive Officer (CEO)
Dr. Muhammad Ali Memon - Chief Medical Officer (CMO)
Jen Watts - Vice President, Clinical Operations
Kathryn Parsley - Vice President, Regulatory Affairs
Scientific Founders:Prof. Paul Bishop (University of Manchester), Prof. Simon Clark (University of Manchester), Prof. Richard Unwin (University of Manchester, Professor of Disease Proteomics as of 2024)
Board Members:Representatives from Gimv, Representatives from Forbion, Industry experts in ophthalmology and biotech
LINKS
Website:complementtx.com
LinkedIn:LinkedIn Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Complement Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Complement Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.